Top Markets
#1 Purr Purr +64.03%
#2 Pons Pons +54.56%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 TENDIES TENDIES +40.15%
#5 Non-Playable Coin Non-Playable Coin +34.25%
#6 Cash Cat Cash Cat +32.21%
#7 Morpho Morpho +26.64%
#8 Kinetiq Kinetiq +23.90%
#9 StonkBroker StonkBroker +22.07%
#10 ApeX ApeX +21.54%
Coin of the day
Purr Purr
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Pozycja w akcjach #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Cena akcji
$2.65
Ostatnia synchronizacja: 2024-04-03
Kapitalizacja rynkowa
$115.71M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Kinnate Biopharma Inc. (KNTE)

Kategoria

Healthcare
Zyski dla Kinnate Biopharma Inc. (KNTE)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Kinnate Biopharma Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Kinnate Biopharma Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH